PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Mateos, M. V., Bahlis, N., Costa, L., Perrot, A., Pei, L., Rubin, M., Lantz, K., Sun, W., Jaffe, M., Kobos, R., Nooka, A.
Publicado 2022

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

por Calimeri, T, Battista, E, Conforti, F, Neri, P, Di Martino, M T, Rossi, M, Foresta, U, Piro, E, Ferrara, F, Amorosi, A, Bahlis, N, Anderson, K C, Munshi, N, Tagliaferri, P, Causa, F, Tassone, P
Publicado 2011

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR...

por Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez-Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.-S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.
Publicado 2022

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

por Dalovisio, A., Bahlis, N., Raje, N., Costello, C., Dholaria, B., Solh, M., Levy, M., Tomasson, M., Dube, H., Damore, M., Jiang, S., Basu, C., Skoura, A., Chan, E., Trudel, S., Jakubowiak, A., Chu, M., Gasparetto, C., Sebag, M., Lesokhin, A.
Publicado 2022

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF T...

por Facon, T., Kumar, S. K., Plesner, T., Moreau, P., Bahlis, N., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Borgsten, F., Usmani, S. Z.
Publicado 2022

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial

por Bahlis, N J, Corso, A, Mugge, L-O, Shen, Z-X, Desjardins, P, Stoppa, A-M, Decaux, O, de Revel, T, Granell, M, Marit, G, Nahi, H, Demuynck, H, Huang, S-Y, Basu, S, Guthrie, T H, Ervin-Haynes, A, Marek, J, Chen, G, Facon, T
Publicado 2017

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY

por Suvannasankha, A., Bahlis, N., Trudel, S., Weisel, K., Koenecke, C., Oriol, A., Voorhees, P. M., Alonso, A. A., Callander, N. S., Mateos Manteca, M. V., Reddy, N., Hakim, S., Patel, N., Williams, D., Jewell, R. C., Zhou, X., Gupta, I., Nooka, A. K.
Publicado 2022

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP...

por Facon, T., Plesner, T., Usmani, S., Kumar, S., Bahlis, N., Hulin, C., Orlowski, R., Nahi, H., Mollee, P., Ramasamy, K., Roussel, M., Jaccard, A., Delforge, M., Karlin, L., Arnulf, B., Chari, A., Pei, H., Gupta, N., Kaila, S., Matt, K., Gries, K., Carson, R., Borgsten, F., Weisel, K., Perrot, A.
Publicado 2023

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMP...

por Delforge, M., Usmani, S. Z., van de Donk, N. W., Garfall, A. L., Moreau, P., Oriol, A., Nooka, A. K., Rosinol, L., Bahlis, N., Rodriguez-Otero, P., Martin, T., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Kobos, R., Slavcev, M., Smit, J., Londhe, A., Krishnan, A.
Publicado 2022

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA...

por Weisel, K., Kumar, S., Moreau, P., Bahlis, N., Facon, T., Plesner, T., Orlowski, R., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C., Raje, N., Tiab1, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Krevvata, M, Carson, R, Borgsten, F., Usmani, S.
Publicado 2023

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

por Jakubowiak, A J, Siegel, D S, Martin, T, Wang, M, Vij, R, Lonial, S, Trudel, S, Kukreti, V, Bahlis, N, Alsina, M, Chanan-Khan, A, Buadi, F, Reu, F J, Somlo, G, Zonder, J, Song, K, Stewart, A K, Stadtmauer, E, Harrison, B L, Wong, A F, Orlowski, R Z, Jagannath, S
Publicado 2013

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON

por Rosinol, L., Usmani, S. Z., Bahlis, N., Krishnan, A. Y., Nooka, A. K., Oriol, A., Delforge, M., Garfall, A. L., van de Donk, N. W., Rodríguez Otero, P., Martin, T. G., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Kobos, R., Slavcev, M., Smit, J., Londhe, A., Moreau, P.
Publicado 2022

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

por Popat, R., Moreau, P., Usmani, S. Z., Garfall, A., Mateos, M.-V., San-Miguel, J. F., Oriol, A., Nooka, A. K., Rosinol, L., Chari, A., Karlin, L., Krishnan, A., Bahlis, N., Martin, T., Besemer, B., Martínez-López, J., Delforge, M., Fastenau, J., Gries, K. S., van de Donk, N. W.
Publicado 2022

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL...

por Rodríguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.
Publicado 2023

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

por van de Donk, N., Cortes-Selva, D., Casneuf, T., Vishwamitra, D., Stein, S., Perova, T., Ramos, E., Van Steenbergen, L., Boominathan, R., Lau, O., Davis, C., Banerjee, A., Stephenson, T., Uhlar, C., Kobos, R., Goldberg, J., Pei, L., Trancucci, D., Girgis, S., Lin, S.X.W., Wu, L.S., Moreau, P., Usmani, S., Bahlis, N.J., Verona, R.
Publicado 2023

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

por Mateos, M, Hari, P, Bahlis, N, Chari, A, van de Donk, NWCJ, Dholaria, B, Garfall, AL, Goldschmidt, H, Kortüm, KM, Krishnan, A, Martin, T, Morillo, D, Oriol, A, Reece, D, Rodriguez, C, Rodríguez-Otero, P, San-Miguel, JF, Usmani, SZ, Verona, R, Lin, SXW, Prior, TJ, Wade, M, Weiss, B, Goldberg, JD, Askari, E
Publicado 2022

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOM...

por Popat, R, Usmani, S, Garfall, A, van de Donk, N, Nahi, H, San-Miguel, J, Oriol, A, Nooka, A, Martin, T, Rosinol, L, Chari, A, Karlin, L, Benboubker, L, Mateos, M, Bahlis, N, Moreau, P, Besemer, B, Martínez-López, J, Sidana, S, Pei, L, Trancucci, D, Verona, R, Girgis, S, Olyslager, Y, Jaffe, M, Uhlar, C, Stephenson, T, Van Rampelbergh, R, Banerjee, A, Goldberg, J, Kobos, R, Krishnan, A
Publicado 2022